We’re excited to see that the FDA has expanded the approval of Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), for nearly all patients. Congrats to Sarepta Therapeutics – this approval marks a significant milestone for patients with #DMD, a genetic disorder characterized by progressive muscle loss. We are proud to work with you! At Aldevron, we envision a world where every cure is possible, and yesterday was a great day! We look forward to witnessing and supporting continued advancements in treatments and cures for patients living with rare and more common diseases.
BREAKING: Today, we announced the U.S. FDA has expanded the product label for our gene therapy and more people may be able to receive treatment. Intended for U.S. audiences